SOX17在细胞学细胞块中对转移性卵巢及子宫内膜癌高敏感高特异
本研究在84例转移性癌的细胞学细胞块标本中验证SOX17免疫组化,其中妇科癌29例、非妇科癌55例。结果显示SOX17在29例转移性妇科癌中均呈弥漫强核表达(100%),在54/55例非妇科癌中阴性(98.18%)。结论认为SOX17是鉴别转移性妇科癌的高敏感(100%)和高特异(98.2%)标志物。
要点
- SOX17在转移性妇科癌中100%弥漫强核表达,敏感度100%。
- SOX17在非妇科癌中98.18%阴性,特异度98.2%。
- 仅1例甲状腺乳头状癌显示低阳性(<10%)。
核心结论
- SOX17是细胞学标本中鉴别转移性妇科癌的高敏感(100%)和高特异(98.2%)标志物。
- SOX17免疫组化应纳入细胞学标本转移性妇科癌鉴别诊断的检查流程。
研究设计与样本
- 研究队列共84例转移性癌,包括29例转移性妇科癌和55例转移性非妇科癌。
- 妇科癌包括24例卵巢高级别浆液性癌、2例子宫内膜浆液性癌、1例低级别浆液性癌、1例卵巢透明细胞癌和1例子宫内膜子宫内膜样癌。
- 非妇科癌包括10例透明细胞肾细胞癌、10例甲状腺乳头状癌、11例胃肠道腺癌、10例乳腺癌、10例肺腺癌和4例尿路上皮癌。
- 细胞学标本类型包括腹膜液(n=44)、胸膜液(n=25)和细针穿刺(n=15),在细胞块切片上行SOX17免疫组化。
主要发现
- SOX17在所有 tested 转移性妇科癌中呈弥漫强核表达(29/29;100%)。
- SOX17在非妇科癌中阴性(54/55;98.18%),仅1例甲状腺乳头状癌显示低阳性(<10%)。
关键数值与推荐
- SOX17敏感度为100%(29/29转移性妇科癌阳性)。
- SOX17特异度为98.2%(54/55非妇科癌阴性)。
临床怎么用
- 在细胞学细胞块标本的转移性妇科癌鉴别诊断中应纳入SOX17免疫组化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SOX17 (SRY-box transcription factor 17) was recently identified as a highly sensitive and specific marker for ovarian and endometrial carcinomas in surgical specimens. In this study, validation of the utility of SOX17 immunohistochemistry (IHC) in diagnosing metastatic gynecologic carcinomas in cytology specimens was sought. METHODS: The study cohort included 84 cases of metastatic carcinomas that included 29 metastatic gynecologic carcinomas (24 ovarian high-grade serous carcinomas, two endometrial serous carcinomas, one low-grade serous carcinoma, one ovarian clear cell carcinoma, and one endometrial endometrioid carcinoma) and 55 cases of metastatic nongynecologic carcinomas (10 clear cell renal cell carcinomas, 10 papillary thyroid carcinomas, 11 gastrointestinal adenocarcinomas, 10 breast carcinomas, 10 lung adenocarcinomas, and four urothelial carcinomas). Cytology specimen types included peritoneal fluid (n = 44), pleural fluid (n = 25), and fine-needle aspiration (n = 15). SOX17 IHC was performed on the cell block sections. The intensity of staining and percent positivity of the tumor cells were evaluated. RESULTS: SOX17 was highly expressed in all tested metastatic gynecologic carcinomas with diffuse and strong nuclear expression (29 of 29; 100%). SOX17 was negative in other metastatic nongynecologic carcinomas (54 of 55; 98.18%) except for one papillary thyroid carcinoma that showed low positivity (<10%). CONCLUSIONS: SOX17 is a highly sensitive (100%) and specific (98.2%) marker for the differential diagnosis of metastatic gynecologic carcinomas in cytology specimens. Therefore, SOX17 IHC should be included in the workup of differential diagnosis of metastatic gynecologic carcinomas in cytology specimens.
引用
- Satturwar S, Shaker N, Sinclair W, et al. SOX17 is a highly sensitive and specific marker for metastatic ovarian and endometrial carcinomas in cytology cell block specimens. Cancer Cytopathol. 2023. PMID: 37195085. doi:10.1002/cncy.22708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。